EUVIMEDEUVIMED entdecken
Open Access

Cost-Effectiveness of Left Ventricular Assist Device for Transplant-Ineligible Patients

Elisabeth M Schaffer, Rebecca Giok Sim Su, Junxing Chay, Eric A Finkelstein

JAMA Network Open · 2025

DOI: 10.1001/jamanetworkopen.2025.4483 ↗

Kurz gefasst

Fachartikel in der Zeitschrift JAMA Network Open, 2025. Verfasst von Elisabeth M Schaffer und 3 weiteren Autor:innen. Beteiligte Einrichtung: Saw Swee Hock School of Public Health, National University of Singapore, Singapore. Hauptthemen laut MEDLINE: Heart-Assist Devices, Cost-Benefit Analysis, Heart Failure. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Importance Singapore is considering subsidizing left ventricular assist devices (LVADs) for end-stage heart failure (ESHF) and uses cost-effectiveness evidence to inform the determination. Yet, no economic evaluation has thus far been conducted.

Objective

To estimate the lifetime cost-effectiveness of LVAD compared with optimal medical management for transplant-ineligible patients. Design, Setting, and Participants This economic evaluation used a Markov model to simulate survival, stroke incidence, other adverse events, and heart failure hospitalizations for a cohort of adult patients in Singapore with transplant-ineligible ESHF, most of whom were inotrope dependent. Latest LVAD mortality data from a randomized clinical trial were age-adjusted, and an indirect comparison of prior trial results was performed to estimate survival for inotrope-dependent and inotrope-independent patients. Costs were estimated (in 2023 Singapore dollars [SGD]) using cohort billing data from 2017 to 2022 and National Heart Centre Singapore LVAD charges. Statistical analysis was performed from December 2023 to July 2024. Exposure HeartMate 3 LVAD (Abbott). Main Outcomes and Measures Health care costs, quality-adjusted life-years (QALYs), and incremental cost-effectiveness ratio (ICER) evaluated against a threshold of SGD 114 000 (US $85 075) per QALY gained.

Results

At model initiation, the cohort had a mean (SD) age of 64 (12) years, and 78% (range, 68%-86%) of patients were inotrope dependent. In the base case analysis, LVAD yielded an additional 3.45 QALYs at an incremental cost of SGD 404 678 (US $301 999), producing an ICER of SGD 117 370 (US $87 590) per QALY gained for the transplant-ineligible population. The ICER differed for inotrope-use subgroups at SGD 106 458 (US $79 446) per QALY gained for inotrope-dependent patients and SGD 174 798 (US $130 446) per QALY gained for inotrope-independent patients (with 59% and 19% probabilities, respectively, of attaining high value). The inotrope-dependent ICER was sensitive to model input changes and structural assumptions, whereas the inotrope-independent ICER consistently exceeded the high-value threshold in scenario analyses. In threshold analyses, a 44% reduction in the total implantation price or a 54% reduction in the all-cause mortality hazard were required for LVAD to be high value for inotrope-independent patients. Confidence that the inotrope-dependent ICER is high value increased to 75% and 85% with respective 20% and 33% reductions in total implantation price. Conclusions and Relevance In this economic evaluation comparing LVAD with optimal medical management, LVAD was potentially high value for most transplant-ineligible patients who are inotrope dependent. Confidence in this result was improved with plausible price reductions, yet only extreme changes rendered LVAD high value for inotrope-independent patients.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Heart-Assist DevicesCost-Benefit AnalysisHeart FailureHumansSingaporeMaleFemaleMiddle AgedQuality-Adjusted Life YearsAgedMarkov ChainsAdultHealth Care Costs

Autor:innen und Institutionen

  • Saw Swee Hock School of Public Health, National University of Singapore, Singapore.
  • Health Services and Systems Research, Duke-NUS Medical School, Singapore.

Zitieren

APA

Schaffer, E. M., Su, R. G. S., Chay, J., & Finkelstein, E. A. (2025). Cost-Effectiveness of Left Ventricular Assist Device for Transplant-Ineligible Patients. JAMA Network Open. https://doi.org/10.1001/jamanetworkopen.2025.4483

Vancouver

Schaffer EM, Su RGS, Chay J, Finkelstein EA. Cost-Effectiveness of Left Ventricular Assist Device for Transplant-Ineligible Patients. JAMA Network Open. 2025. doi:10.1001/jamanetworkopen.2025.4483

BibTeX
@article{Schaffer2025,
  author = {Schaffer, Elisabeth M and Su, Rebecca Giok Sim and Chay, Junxing and Finkelstein, Eric A},
  title = {Cost-Effectiveness of Left Ventricular Assist Device for Transplant-Ineligible Patients},
  journal = {JAMA Network Open},
  year = {2025},
  doi = {10.1001/jamanetworkopen.2025.4483}
}
Kostenlos starten →